MX2015016024A - Formulacion en nanoparticulas que comprende un antagonista para trpa1. - Google Patents

Formulacion en nanoparticulas que comprende un antagonista para trpa1.

Info

Publication number
MX2015016024A
MX2015016024A MX2015016024A MX2015016024A MX2015016024A MX 2015016024 A MX2015016024 A MX 2015016024A MX 2015016024 A MX2015016024 A MX 2015016024A MX 2015016024 A MX2015016024 A MX 2015016024A MX 2015016024 A MX2015016024 A MX 2015016024A
Authority
MX
Mexico
Prior art keywords
nanoparticulate formulation
trpa1 antagonist
formulation
trpa1
antagonist
Prior art date
Application number
MX2015016024A
Other languages
English (en)
Inventor
Ulhas Dhuppad
Sunil Chaudhari
Suresh Rajurkar
Nilesh Jain
Original Assignee
Glenmark Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa
Publication of MX2015016024A publication Critical patent/MX2015016024A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención hace referencia a una formulación en nanopartículas que comprende un antagonista para el receptor de anquirina-1 de potencial de receptor transitorio ("TRPA1"). En particular, la presente invención hace referencia a una formulación en nanopartículas que comprende un derivado de tienopirimidinadiona como un antagonista para TRPA1 y un estabilizador de superficie; un proceso para preparar ese tipo de formulación; y su uso para el tratamiento de un trastorno o dolor respiratorio en un sujeto.
MX2015016024A 2013-06-20 2014-06-20 Formulacion en nanoparticulas que comprende un antagonista para trpa1. MX2015016024A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2090MU2013 2013-06-20
PCT/IB2014/062462 WO2014203210A1 (en) 2013-06-20 2014-06-20 Nanoparticulate formulation comprising a trpa1 antagonist

Publications (1)

Publication Number Publication Date
MX2015016024A true MX2015016024A (es) 2016-04-04

Family

ID=51136536

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015016024A MX2015016024A (es) 2013-06-20 2014-06-20 Formulacion en nanoparticulas que comprende un antagonista para trpa1.

Country Status (13)

Country Link
US (1) US10603277B2 (es)
EP (1) EP3010489A1 (es)
JP (1) JP2016522251A (es)
CN (1) CN105307642A (es)
AP (1) AP2015008919A0 (es)
AU (1) AU2014282762B2 (es)
BR (1) BR112015030341A2 (es)
CA (1) CA2912578A1 (es)
EA (1) EA201592120A1 (es)
HK (1) HK1221161A1 (es)
MX (1) MX2015016024A (es)
PH (1) PH12015502820A1 (es)
WO (1) WO2014203210A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190175599A1 (en) * 2014-09-16 2019-06-13 Glemark Pharmaceuticals S.A. Trpa1 antagonist for the treatment of pain associated to diabetic neuropathic pain
PL3568122T3 (pl) * 2017-01-10 2024-03-18 Dukebox Sp. Z O.O. Sposób wytwarzania zawiesiny nanocząsteczek soli potasowej albo soli magnezowej
CA3110773C (en) * 2018-09-11 2023-02-28 Lead Biotherapeutics Ltd. Mucoadhesive dispersion nanoparticle system and method for production the same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
IT1298575B1 (it) * 1998-02-06 2000-01-12 Vectorpharma Int Composizioni farmaceutiche in forma di nanoparticelle comprendenti sostanze lipidiche e sostanze antifiliche e relativo processo di
US8771740B2 (en) * 1999-12-20 2014-07-08 Nicholas J. Kerkhof Process for producing nanoparticles by spray drying
US7998507B2 (en) 2000-09-21 2011-08-16 Elan Pharma International Ltd. Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
UA76810C2 (uk) 2001-12-10 2006-09-15 Мерк Енд Ко., Інк. Фармацевтична композиція антагоніста рецептора тахікініну у формі наночастинок
CA2598288A1 (en) 2005-03-03 2006-09-14 Elan Pharma International Limited Nanoparticulate compositions of heterocyclic amide derivatives
KR20070118258A (ko) * 2005-03-16 2007-12-14 엘란 파마 인터내셔널 리미티드 나노입자형 류코트리엔 수용체안타고니스트/코르티코스테로이드 제제
EA201190191A1 (ru) 2009-03-23 2012-11-30 Гленмарк Фармасьютикалс, С.А. Изотиазоло-пиримидинедионовые производные в качестве модуляторов trpa1
WO2010109329A1 (en) 2009-03-23 2010-09-30 Glenmark Pharmaceuticals, S.A. Furopyrimidinedione derivatives as trpa1 modulators
WO2010141805A1 (en) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Heterocyclic amides as modulators of trpa1
WO2011043954A1 (en) 2009-10-07 2011-04-14 Merck Sharp & Dohme Corp. Novel trpa1 antagonists
WO2012176105A1 (en) * 2011-06-22 2012-12-27 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising a trpa1 antagonist and a leukotriene receptor antagonist
AU2013273118B2 (en) * 2012-06-08 2015-11-05 Glenmark Pharmaceuticals S.A. Amides of 2-amino-4-arylthiazole compounds and their salts

Also Published As

Publication number Publication date
AU2014282762A1 (en) 2015-11-26
AP2015008919A0 (en) 2015-12-31
CN105307642A (zh) 2016-02-03
EP3010489A1 (en) 2016-04-27
US20140377358A1 (en) 2014-12-25
HK1221161A1 (zh) 2017-05-26
PH12015502820A1 (en) 2016-03-21
EA201592120A1 (ru) 2016-04-29
WO2014203210A1 (en) 2014-12-24
US10603277B2 (en) 2020-03-31
BR112015030341A2 (pt) 2017-07-25
JP2016522251A (ja) 2016-07-28
AU2014282762B2 (en) 2016-11-10
CA2912578A1 (en) 2014-12-24

Similar Documents

Publication Publication Date Title
MX2019005192A (es) Compuestos de quinolina selectivamente sustituida.
MX2021008113A (es) Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma.
MX369770B (es) Compuestos agonistas triples de glucagón-glp-1-gip.
MX368455B (es) Compuestos de tetrahidropirazolopirimidina.
PH12015502788A1 (en) Antibody formulations and methods
PH12020500255A1 (en) Use of nk-1 receptor antagonist serlopitant in pruritus
CL2015001358A1 (es) Potenciadores del cftr deuterados
MX363708B (es) Compuestos de quinolina selectivamente sustituidos.
IL245101A0 (en) Derivatives of 1,4-cyclohexylamine and processes for their preparation
PH12016501122A1 (en) Delayed release compositions of linaclotide
MX2018003893A (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
MX2016004540A (es) Tiazolopirimidinonas como moduladores de la actividad de receptores de n-metil-d-aspartato (nmda).
MX2016004741A (es) Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico.
CY1121238T1 (el) Παραγωγα παντοθενικου για την αντιμετωπιση νευρολογικων διαταραχων
PH12015502820A1 (en) Nanoparticulate formulation comprising a trpa1 antagonist
MX2016001104A (es) Composiciones para tratar engrosamiento de la piel.
NZ707946A (en) Hydantoin derivative
PH12015502029A1 (en) Phenylephrine resinate particles and use thereof in pharmaceutical formulations
IN2013DE03665A (es)
HUE056121T2 (hu) Kompozíció UV-B terápia hatékonyságának növelésére, eljárás annak elõállítására, és alkalmazása
GB2533741A (en) Locking apparatus
UA105608C2 (uk) Спосіб антицелюлітного обгортання за індріксоном
IN2013CH00453A (es)